Pfizer Faces Penicillin Donation Non-Compliance; US Proposes Medicare Drug Negotiation Changes; Germany Maintains Drug Cost Caps
Pfizer has not complied with a request from state health agencies to donate emergency penicillin, intended to prevent congenital syphilis. Meanwhile, the Trump administration has proposed changes to a Medicare policy aimed at preventing drugmakers from circumventing price negotiations by combining active ingredients. This proposal is part of an annual rule for selecting drugs for negotiation, with prices taking effect in 2029. Separately, German Health Minister Nina Warken confirmed that pharmaceutical companies would not be exempt from new cost-cutting measures, despite industry warnings about launching innovative medicines in Europe. Germany's proposed legislation seeks to cap rising costs in its statutory health insurance system.
Pfizer has not complied with a request to donate emergency penicillin to state health agencies. This donation was intended to serve as a backstop to help prevent congenital syphilis.
The Trump administration has proposed changes to a policy designed to prevent drugmakers from avoiding Medicare price negotiation. The current policy allows companies to add active ingredients to drugs, which can lead the FDA to classify the resulting combination as a new product, thereby granting additional time before price negotiation takes effect.
This proposal is part of an annual proposed rule that establishes the process for the Centers for Medicare and Medicaid Services (CMS) to choose the next 20 drugs and biologics for price negotiation. These selections are scheduled for announcement by February 1, 2027, with their negotiated prices taking effect in 2029. The administration's proposal specifically aims to subject certain types of combination biologics to negotiation in some cases.
In Germany, Health Minister Nina Warken stated that drugmakers would not be exempted from forthcoming cost-cutting measures. This announcement follows warnings from some pharmaceutical companies that they may be unable to launch innovative medicines in Europe unless governments agree to pay more than they historically have.
Proposed legislation in Germany aims to cap rapidly growing costs within the statutory health insurance system. Warken acknowledged that many drug companies are under pressure and that the planned legislation would not bring them extra revenue. However, she maintained that Germany remains an attractive location for the pharmaceutical industry due to reimbursement under the statutory health insurance scheme and opportunities for clinical trials, making exemptions from the proposed legislation "out of the question."
According to STAT News, these developments highlight ongoing tensions between pharmaceutical companies and government health agencies regarding drug pricing and supply.
